Sou Hu Cai Jing·2025-11-12 00:31Core Insights - Spring Medical (688236) closed at 27.09 yuan on November 11, 2025, down 3.25% with a trading volume of 29,400 hands and a transaction amount of 80.51 million yuan [1][2] Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 756 million yuan, a year-on-year increase of 48.75% [4] - The net profit attributable to shareholders was 192 million yuan, up 213.21% year-on-year, while the net profit after deducting non-recurring gains and losses was 181 million yuan, an increase of 311.07% [4] - In Q3 2025, the company achieved a single-quarter main revenue of 268 million yuan, a year-on-year increase of 109.51%, and a net profit of 77.06 million yuan, up 531.12% year-on-year [4] Market Position - The total market value of Spring Medical is 10.39 billion yuan, ranking 37th in the medical device industry [4] - The company has a net asset of 2.99 billion yuan, ranking 51st, and a net profit of 192 million yuan, ranking 33rd [4] - The company's price-to-earnings ratio (P/E) is 40.69, which is lower than the industry average of 62.82, ranking 43rd [4] Investment Sentiment - In the last 90 days, 9 institutions rated the stock, with 8 buy ratings and 1 hold rating, and the average target price set by institutions is 30.65 yuan [5] - On November 11, 2025, the net inflow of main funds was 3.15 million yuan, accounting for 3.91% of the total transaction amount [1][2]